Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India

Ramesh Joga, Sravani Yerram, Jayasri Devi Patnam, Khushbhoo K. Choudhary, Priya Varpe, Rajeev Singh Raghuvanshi and Saurabh Srivastava

Health Policy, 2025, vol. 161, issue C

Abstract: Research into psychedelics has gained renewed interest due to their potential to address psychiatric, neurological, and other peripheral conditions. These substances offer long-term therapeutic benefits, contrasting with the side effects and limitations of current psychiatric medicines.

Keywords: Psilocybin; NMDA antagonist; Ketamine; TGA; Health Canada; NDPS act; MDMA; DMT; LSD (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851025001472
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:161:y:2025:i:c:s0168851025001472

DOI: 10.1016/j.healthpol.2025.105392

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().